EViS Bioscience is pleased to share an important recognition received by our Co-founder and CTO, Elita Montanari. Her scientific work, published in Advanced Science and titled “Loading of Extracellular Vesicles with Nucleic Acids via Hybridization with Non-Lamellar Liquid Crystalline Lipid Nanoparticles”, has been recognized by Wiley as a Top Viewed Article 2025. This achievement highlights…
EViS Bioscience has been featured in Milano Finanza in relation to its upcoming capital increase, aimed at accelerating the development of its proprietary RNA delivery platform. The article outlines how the company is addressing one of the most critical challenges in RNA therapeutics: achieving precise, efficient, and safe delivery of genetic material to target cells….
EViS Bioscience has been featured in a recent article by Startup News Italia, highlighting its innovative approach to targeted RNA delivery and its role within the evolving precision medicine landscape. The article focuses on one of the key challenges in RNA-based therapeutics: the ability to deliver genetic material safely and efficiently to specific cells. EViS…
Campaign reaches 105.5% of target, strengthening EVis’s position in next-generation RNA therapeutics EVis Bioscience AG has successfully closed its pre-seed funding round on Capital Cell, raising €740,000 and surpassing the original funding target at 105.5%. The campaign attracted strong support from private and professional investors across Europe, reflecting growing confidence in EVis’s hybrid RNA delivery…
EVis Bioscience has been awarded the title “Top Targeted Gene Therapy Medicines Development Company in Europe 2026” by Life Sciences Review Europe, recognizing its leadership in precision RNA therapeutic development. The award acknowledges companies demonstrating technological differentiation, translational relevance, and measurable innovation within the European gene therapy sector. Why EVis Was Selected The recognition highlights…
EVis Bioscience has been featured by Life Sciences Review Europe for its innovative approach to RNA delivery and targeted gene therapy. The editorial highlights the company’s differentiated technological strategy and its potential impact on next-generation therapeutic development. At the core of the feature is EVis Bioscience’s hybrid RNA delivery platform, which integrates stabilized extracellular vesicles…
We are pleased to share a new feature about EVis Bioscience AG published by Fortune Italia, highlighting how our technology is helping shape the future of precision medicine based on RNA therapeutics. The article explores the scientific vision behind EVis: developing advanced non-viral delivery systems capable of directing therapeutic RNA safely and selectively to specific…
We are excited to share an interview published on Osservatorio Terapie Avanzate, where our CTO Prof. Elita Montanari discusses our innovative approach to targeted RNA delivery. In the rapidly evolving field of RNA therapies, we believe that precision in delivery is key to enhancing both efficacy and safety. In the interview, we explore how our…
We are proud to share that EVis Bioscience has been featured in la Repubblica‘s “Lab Revolution” series, highlighting our innovative approach to gene therapy for rare diseases. Founded in June 2024 by Italian researchers Elita Montanari with investor Tommaso Caselli, EVis Bioscience is a spin-off from ETH Zurich. Our mission is to develop next-generation non-viral…
A recent study published on Exosome RNA introduces a novel method for efficiently loading nucleic acids into extracellular vesicles (EVs). This technique involves the spontaneous hybridization of EVs with preloaded non-lamellar liquid crystalline lipid nanoparticles (LCNPs) under physiological conditions, resulting in the formation of hybrid extracellular vesicles (HEVs). Key findings from the study include: This…